BioCentury | Dec 5, 2017
Distillery Therapeutics

Renal

...doi:10.1038/s41467-017-01646-6 CONTACT: Zhaoyong Hu, Baylor College of Medicine, Houston, Texas email: zhaoyonh@bcm.edu Hongjiang Li Baylor College of Medicine Fibronectin type III domain containing 5 (FNDC5) (irisin) Peroxisome...
BioCentury | Mar 10, 2016
Targets & Mechanisms

Brown fat heats up

While FGF21 is the clear frontrunner target for stimulating brown and beige fat, players in the seven year-old field believe there's room for plenty more runners in the race. Since the start of the year,...
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Fibronectin type III domain containing 5 (FNDC5; irisin)

Musculoskeletal disease INDICATION: Musculoskeletal Mouse studies suggest the skeletal muscle-derived myokine FNDC5 could help treat osteoporosis and other forms of bone loss. In normal mice, injection of human-mouse chimeric FNDC5 increased cortical bone mass and...
BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Fibronectin type III domain containing 5 (FNDC5; irisin) A study in mice and in patient serum identified irisin...
Items per page:
1 - 4 of 4